» Articles » PMID: 36013184

CD24: A Novel Target for Cancer Immunotherapy

Overview
Journal J Pers Med
Date 2022 Aug 26
PMID 36013184
Authors
Affiliations
Soon will be listed here.
Abstract

Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor CD24 expression has been linked with alterations in several oncogenic signaling pathways. In addition, the CD24/Siglec-10 interaction has been implicated in tumor immune evasion, inhibiting macrophage-mediated phagocytosis as well as natural killer (NK) cell cytotoxicity. CD24 blockade has shown promising results in preclinical studies. Although there are limited data on efficacy, monoclonal antibodies against CD24 have demonstrated clinical safety and tolerability in two clinical trials. Other treatment modalities evaluated in the preclinical setting include antibody-drug conjugates and chimeric antigen receptor (CAR) T cell therapy. In this review, we summarize current evidence and future perspectives on CD24 as a potential target for cancer immunotherapy.

Citing Articles

The Immunoexpression and Prognostic Significance of Stem Cell Markers in Malignant Salivary Gland Tumors: A Systematic Review and Meta-Analysis.

Kalogirou E, Tosiou A, Vrachnos S, Zogopoulos V, Michalopoulos I, Tzanavari T Genes (Basel). 2025; 16(1).

PMID: 39858584 PMC: 11764928. DOI: 10.3390/genes16010037.


MicroRNA Profiling of PRELI-Modulated Exosomes and Effects on Hepatic Cancer Stem Cells.

Kim B Int J Mol Sci. 2025; 25(24.

PMID: 39769068 PMC: 11678812. DOI: 10.3390/ijms252413299.


miR-210 Mediated Hypoxic Responses in Pancreatic Ductal Adenocarcinoma.

Mortoglou M, Lian M, Miralles F, Dart D, Uysal-Onganer P ACS Omega. 2024; 9(48):47872-47883.

PMID: 39651070 PMC: 11618397. DOI: 10.1021/acsomega.4c08947.


Cheminformatic Identification of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) Inhibitors: A Comparative Study of SMILES-Based Supervised Machine Learning Models.

Lai C, Kwok A, Wong K J Pers Med. 2024; 14(9).

PMID: 39338235 PMC: 11433629. DOI: 10.3390/jpm14090981.


Multidimensional analysis of tumor stem cells: from biological properties, metabolic adaptations to immune escape mechanisms.

Han H, He T, Wu Y, He T, Zhou W Front Cell Dev Biol. 2024; 12:1441081.

PMID: 39184916 PMC: 11341543. DOI: 10.3389/fcell.2024.1441081.


References
1.
Myung J, Gajjar K, Pearson R, Launiere C, Eddington D, Hong S . Direct measurements on CD24-mediated rolling of human breast cancer MCF-7 cells on E-selectin. Anal Chem. 2011; 83(3):1078-83. PMC: 3059340. DOI: 10.1021/ac102901e. View

2.
Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M . CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006; 131(2):630-9. DOI: 10.1053/j.gastro.2006.04.028. View

3.
Liu M, Wang X, Du X, Zhang Y, Ai C, Hu-Lieskovan S . CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal Transduct Target Ther. 2022; 7(1):224. PMC: 9283527. DOI: 10.1038/s41392-022-01030-x. View

4.
Salnikov A, Bretz N, Perne C, Hazin J, Keller S, Fogel M . Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer. 2013; 108(7):1449-59. PMC: 3629417. DOI: 10.1038/bjc.2013.102. View

5.
Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y . Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci. 2010; 57(2):165-75. View